Clinlab.AI will oversee every aspect of this new-look laboratory, working to integrate it with the practice's workflows in a way that boosts patient care and speeds up treatment decisions.
More than 33,000 devices are affected by this recall. Customers may need to return and replace the purge cassettes included with their devices due to a risk of serious injury or death.
Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.
A new embolic protection device from Emboline was noninferior to the FDA-approved Sentinel device in terms of safety and efficacy. In addition, it captured much more TAVR-generated debris and was linked to an improved technical success rate.
Greg Piefer, PhD, chief executive and founder of Shine, a Wisconsin-based radiopharmaceutical company that is building the world’s largest medical isotope production facility in Janesville, Wisconsin, explains progress on the company's fusion reactor that will become the first sustained U.S. commercial supplier of molybdenum-99 in decades.
Cardiology is number one in FDA Breakthrough Device designations at 218, the highest number out of all other clinical categories. This includes 16 new devices cleared in the past year.
Edwards Lifesciences asked the U.S. Federal Trade Commission (FTC) this week to dismiss the complaint against the company's acquisition of JenaValve this week. A healthcare market analysis firm also said the FTC actions will likely impact the timing of an FDA clearance of the Trilogy heart valve.
